Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor

Platelets

Volumn 27, Issue 6, 2016, Pages 576-582

  Verdoia, Monica ^a   Pergolini, Patrizia ^a   Rolla, Roberta ^a   Sartori, Chiara ^a   Nardin, Matteo ^a   Schaffer, Alon ^a   Barbieri, Lucia ^a   Daffara, Veronica ^a   Marino, Paolo ^a   Bellomo, Giorgio ^a   Suryapranata, Harry ^b   Luca, Giuseppe De ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clopidogrel; coronary artery disease; dual antiplatelet therapy; platelet aggregation; ticagrelor; vitamin D

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICAGRELOR; TRIACYLGLYCEROL; VITAMIN D; ADENOSINE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGE; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD EXAMINATION; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY SURGERY; DIABETES MELLITUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RESIDUAL PLATELET REACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; ODDS RATIO; THROMBOCYTE; THROMBOCYTE ACTIVATION; VERY ELDERLY;

ADENOSINE; ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PLATELETS; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; VITAMIN D;

EID: 84962812229     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2016.1149159     Document Type: Article

References (48)

1. G.De Luca, F.Bellandi, K.Huber, M.Noc, A.S.Petronio, H.R.Arntz, M.Maioli, H.M.Gabriel, S.Zorman, D.E.Carlo M, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation:individual patient’s data meta-analysis. J Thromb Haemost 2011;9:2361–2370.
2. G.De Luca, E.Cassetti, M.Verdoia, P.Marino Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty:A meta-analysis of randomised trials. Thromb Haemost 2009;102:428–436.
3. G.De Luca, M.Dirksen, C.Spaulding, H.Kelbaek, M.Schalij, L.Thuesen, B.van der Hoeven, M.A.Vink, C.Kaiser, C.Musto, et al. Drug-eluting versus bare metal stents in primary angioplasty:A pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012;172:611–621.
4. K.W.Park, K.H.Jeon, S.H.Kang, I.Y.Oh, H.J.Cho, H.Y.Lee, H.J.Kang, S.K.Park, B.K.Koo, B.H.Oh, et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011;108:1556–1563.
5. T.Cuisset, C.Frere, J.Quilici, P.E.Morange, L.Nait-Saidi, C.Mielot, L.Bali, M.Lambert, M.C.Alessi, J.L.Bonnet High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007;97:282–287.
6. S.D.Wiviott, E.Braunwald, C.H.McCabe, G.Montalescot, W.Ruzyllo, S.Gottlieb, F.J.Neumann, D.Ardissino, S.De Servi, S.A.Murphy, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
7. L.Wallentin, R.C.Becker, A.Budaj, C.P.Cannon, H.Emanuelsson, C.Held, J.Horrow, S.Husted, S.James, H.Katus, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
8. M.Verdoia, A.Schaffer, E.Cassetti, L.Barbieri, R.Piccolo, G.Galasso, P.Marino, F.Finigaglia, G.De Luca Benefits from new ADP-antagonists as compared to clopidogrel in patients with stable angina or acute coronary syndrome:A meta-analysis of randomized trials. J Cardiovasc Pharmacol 2013. [Epub ahead of Print].
9. E.Giovannucci, Y.Liu, B.W.Hollis, E.B.Rimm 25-hydroxyvitamin D and risk of myocardial infarction in men:A prospective study. Arch Intern Med 2008;168:1174–1180.
10. O.Tarcin, D.G.Yavuz, B.Ozben, A.Telli, A.V.Ogunc, M.Yuksel, A.Toprak, D.Yazici, S.Sancak, O.Deyneli, S.Akalin Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009;94:4023–4030.
11. C.G.Buitrago, N.S.Arango, R.L.Boland 1α,25(OH)2D3-dependent modulation of Akt in proliferating and differentiating C2C12 skeletal muscle cells. J Cell Biochem 2012;113:1170–1181.
12. E.van Etten, C.Mathieu Immunoregulation by 1,25-dihydroxyvitamin D3:basic concepts. J Steroid Biochem Mol Biol 2005;97:93–101.
13. F.Silvagno, E.De Vivo, A.Attanasio, V.Gallo, G.Mazzucco, G.Pescarmona Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One 2010;5:e8670.
14. G.De Luca, G.G.Secco, M.Santagostino, L.Venegoni, S.Iorio, E.Cassetti, M.Verdoia, L.Coppo, C.Di Mario, G.Bellomo, et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012;22:426–433.
15. M.F.Holick Vitamin D deficiency. N Engl J Med 2007;357:266–281.
16. M.Verdoia, P.Pergolini, C.Camaro, M.Restifo, R.Rolla, A.Schaffer, G.Di Giovine, P.Marino, G.Bellomo, H.Suryapranata, et al. Novara Atherosclerosis Study Group (NAS). PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013;24:411–418.
17. M.Vidali, R.Rolla, M.Parrella, C.Cassani, M.Manzini, M.R.Portalupi, R.Serino, M.D.Prando, G.Bellomo, P.Pergolini Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012;34:484–494.
18. D.Sibbing, S.Braun, T.Morath, J.Mehilli, W.Vogt, A.Schömig, A.Kastrati, N.von Beckerath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849–856.
19. L.Bonello, U.S.Tantry, R.Marcucci, R.Blindt, D.J.Angiolillo, R.Becker, D.L.Bhatt, M.Cattaneo, J.P.Collet, T.Cuisset, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.
20. G.De Luca, van ‘t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005;26:662–666.
21. G.De Luca, J.J.Smit, N.Ernst, H.Suryapranata, J.P.Ottervanger, J.C.Hoorntje, J.H.Dambrink, A.T.Gosslink, M.J.de Boer, van ‘t Hof AW. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005;93:820–823.
22. G.De Luca, M.Verdoia, H.Suryapranata Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty:A meta-analysis of 8 randomized trials. Atherosclerosis 2012;222:426–433.
23. G.De Luca, M.T.Dirksen, C.Spaulding, H.Kelbæk, M.Schalij, L.Thuesen, B.van der Hoeven, M.A.Vink, C.Kaiser, C.Musto, et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013;110:826–833.
24. G.W.Stone, B.Witzenbichler, G.Weisz, M.J.Rinaldi, F.J.Neumann, D.C.Metzger, T.D.Henry, D.A.Cox, P.L.Duffy, E.Mazzaferri, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):A prospective multicentre registry study. Lancet 2013;382:614–623.
25. U.S.Tantry, L.Bonello, D.Aradi, M.J.Price, Y.H.Jeong, D.J.Angiolillo, G.W.Stone, N.Curzen, T.Geisler, J.Ten Berg, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273.
26. G.Patti, F.Mangiacapra, E.Ricottini, A.Cannatà, I.Cavallari, V.Vizzi, A.D’Ambrosio, G.Dicuonzo, G.Di Sciascio Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). Am J Cardiol 2013;111:1739–1744.
27. I.Muller, F.Besta, C.Schulz, S.Massberg, A.Scho¨mig, M.Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783–787.
28. D.J.Angiolillo, A.Fernandez-Ortiz, E.Bernardo, F.Alfonso, C.Macaya, T.A.Bass, M.A.Costa Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505–1516.
29. M.F.Holick, L.Y.Matsuoka, W.J.AgeWortsman J., vitamin D, and solar ultraviolet. Lancet 1989;2:1104–1105.
30. M.F.Holick, J.A.MacLaughlin, S.H.Doppelt Regulation of cutaneous previtamin D3 photosynthesis in man:Skin pigment is not an essential regulator. Science 1981;211:590–593.
31. S.G.Rostand, T.B.Drueke Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383–339.
32. A.Cardus, S.Panizo, M.Encinas, X.Dolcet, C.Gallego, M.Aldea, E.Fernandez, J.M.Valdivielso 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009;204:85–89.
33. S.SSSchleithoff, A.Zittermann, G.Tenderich, B.HKBerthold, P.Stehle, R.Koerfer Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure:A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754–759.
34. K.Aihara, H.Azuma, M.Akaike, Y.Ikeda, M.Yamashita, T.Sudo, H.Hayashi, Y.Yamada, F.Endoh, M.Fujimura, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279:35798–35802.
35. K.Aihara, H.Azuma, T.Matsumoto [Vitamin D-vitamin D receptor system regulates antithrombogenicity in vivo]. Clin Calcium 2006;16:1173–1179.
36. A.J.López-Farré, P.J.Mateos-Cáceres, D.Sacristán, L.Azcona, E.Bernardo, T.P.de Prada, S.Alonso-Orgaz, M.Fernández-Arquero, A.Fernández-Ortiz, C.Macaya Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients:A proteomic study. J Proteome Res 2007;6:2481–2487
37. D.Chadha, B.Sumana, A.G.Karthikeyan G, V.Jayaprasad, A.SSArun. Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. Catheter Cardiovasc Interv 2014. [Epub ahead of print].
38. C.Karohl, V.Vaccarino, E.Veledar, J.Goldberg, V.Tangpricha, A.Bellasi, P.Raggi Vitamin D status and coronary flow reserve measured by positron emission tomography:A co-twin control study. J Clin Endocrinol Metab 2013;98:389–397.
39. S.Nylander, E.A.Femia, M.Scavone, P.Berntsson, A.K.Asztély, K.Nelander, L.Löfgren, R.G.Nilsson, M.Cattaneo Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013;11:1867–1876.
40. M.A.Ventura, T.P.ADPThomopoulos P. and ATP activate distinct signaling pathways in human promonocytic U-937 cells differentiated with 1,25-dihydroxy-vitamin D3. Mol Pharmacol 1995;47:104–114.
41. A.Sinha, K.G.Hollingsworth, S.Ball, T.Cheetham Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J Clin Endocrinol Metab 2013;98(3):E509–E513.
42. O.Borst, P.Muenzer, E.Schmid, A.Russo, B.Walker, W.Yang, C.Leibrock, K.Szteyn, S.Schmidt, A.Russo, et al. 1,25(OH)2 vitamin D3 dependent inhibition of platelet Ca2+ signaling and thrombus formation on klotho-deficient mice. FASEB J 2014;28:2108–2119.
43. S.N.Verouti, A.B.Tsoupras, F.Alevizopoulou, C.A.Demopoulos, C.Iatrou Paricalcitol effects on activities and metabolism of platelet activating factor and on inflammatory cytokines in hemodialysis patients. Int J Artif Organs 2013;36(2):87–96.
44. J.Silvain, G.Cayla, J.S.Hulot, J.Finzi, M.Kerneis, S.A.O’Connor, A.Bellemain-Appaix, O.Barthélémy, F.Beygui, J.P.Collet, et al. High on-thienopyridine platelet reactivity in elderly coronary patients:The SENIOR-PLATELET study. Eur Heart J 2012;33:1241–1249.
45. L.Bonello, J.Mancini, M.Pansieri, L.Maillard, P.Rossi, F.Collet, B.Jouve, O.Wittenberg, M.Laine, P.Michelet, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012;10:1999–2005.
46. L.Bonello, M.Laine, K.Baumstarck, J.Fernandez, L.Maillard, M.Peyrol, J.Bessereau, D.Aradi, E.Camilleri, F.Roubille, et al. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. Int J Cardiol 2013;168:4244–4248.
47. J.M.Siller-Matula, G.Delle-Karth, I.M.Lang, T.Neunteufl, M.Kozinski, J.Kubica, G.Maurer, K.Linkowska, T.Grzybowski, K.Huber, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety:The PEGASUS-PCI study. J Thromb Haemost 2012;10:529–542.
48. J.M.Siller-Matula, C.Gruber, M.Francesconi, C.Dechant, B.Jilma, G.Delle-Karth, K.Grohs, A.Podczeck-Schweighofer, G.Christ The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond) 2015; 128:121–130.